cifenline has been researched along with Recrudescence in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to compare the efficacy and safety of cibenzoline (130 mg twice a day) and sustained-release hydroquinidine (300 mg twice a day) in the prevention of recurrent atrial fibrillation (AF)." | 9.08 | [Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study]. ( Brembilla-Perrot, B; Gabriel, A; Lardoux, H; Levy, S; Marchand, X; Scheck, F; Touboul, P, 1995) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 9.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 9.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "The probability of absence of recurrence at 6 months was 36 +/- 11% in Group C and 55 +/- 10% in Group D (p = NS)." | 6.69 | [A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia]. ( Baudouy, Y; Bine-Scheck, F; Cheikel, J; Dambrine, P; Flammang, D; Graux, P; Jouannon, C; Leenhardt, A; Piot, O, 1998) |
| "The objective of this study was to compare the efficacy and safety of cibenzoline (130 mg twice a day) and sustained-release hydroquinidine (300 mg twice a day) in the prevention of recurrent atrial fibrillation (AF)." | 5.08 | [Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study]. ( Brembilla-Perrot, B; Gabriel, A; Lardoux, H; Levy, S; Marchand, X; Scheck, F; Touboul, P, 1995) |
| "This multicentre, randomized, double-blind study, conducted in parallel groups, was designed to compare the efficacy and safety of cibenzoline (C) and oral propafenone (P) in the prevention of recurrent atrial arrhythmias (M) over a 6-month period." | 5.08 | [Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study]. ( Bleinc, D; Canler, A; Lardoux, H; Maison Blanche, P; Marchand, X; Péraudeau, P; Rouesnel, P; Scheck, F, 1996) |
| "The efficacy of oral cibenzoline (260 mg/day and 320 mg/day) and flecainide (200 mg/day and 300 mg/day) in the conversion of chronic atrial fibrillation to sinus rhythm were compared in 31 patients in a randomized order." | 5.07 | Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation. ( Kühlkamp, V; Risler, T; Schmid, F; Seipel, L, 1991) |
| "The probability of absence of recurrence at 6 months was 36 +/- 11% in Group C and 55 +/- 10% in Group D (p = NS)." | 2.69 | [A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia]. ( Baudouy, Y; Bine-Scheck, F; Cheikel, J; Dambrine, P; Flammang, D; Graux, P; Jouannon, C; Leenhardt, A; Piot, O, 1998) |
| "Seventeen patients had documented recurrence of atrial arrhythmia (9 in the cibenzoline group, 8 in the flecainide group) during the study." | 2.68 | Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study. ( Babuty, D; D'Hautefeuille, B; Mycinsky, C; Peraudeau, P; Pruvost, P; Scheck, F, 1995) |
| "In 21 patients (17%) recurrence was documented by ECG or Holter monitoring, cibenzoline thus being effective in 83%." | 2.68 | Cibenzoline in the prevention of recurrence of supraventricular arrhythmias. ( el Allaf, D; Kormoss, N; Schifflers, E, 1995) |
| "In the not-responders, the mean time to recurrence was 75 +/- 48 days in group C and 75 +/- 62 days in group F(NS)." | 2.68 | [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias]. ( Babuty, D; Brembilla-Perrot, B; Breuillac, JC; Fauchier, JP; Funck, F; Garnier, LF; Maison-Blanche, P; Medvedowsky, JL; Peraudeau, P; Rouesnel, P; Scheck, F, 1997) |
| "The electrocardiographic (ECG) and electrophysiologic (EP) effects, clinical efficacy and safety of oral cibenzoline therapy were evaluated using a twice-daily dosing regimen in patients with refractory ventricular tachycardia (VT)." | 2.66 | Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia. ( Rothbart, ST; Saksena, S, 1986) |
| "Cibenzoline prevented the recurrence of ventricular tachycardia in five patients (18%)." | 1.27 | Antiarrhythmic use of cibenzoline, a new class 1 antiarrhythmic agent with class 3 and 4 properties, in patients with recurrent ventricular tachycardia. ( Bulgarelli, R; Cocco, G; Kamal Al Yassini, A; Padula, A; Pansini, R; Rochat, N; Sfrisi, C; Strozzi, C, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (23.08) | 18.7374 |
| 1990's | 9 (69.23) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komatsu, T | 1 |
| Sato, Y | 1 |
| Tachibana, H | 1 |
| Nakamura, M | 1 |
| Horiuchi, D | 1 |
| Okumura, K | 1 |
| Cocco, G | 1 |
| Strozzi, C | 1 |
| Pansini, R | 1 |
| Rochat, N | 1 |
| Bulgarelli, R | 1 |
| Padula, A | 1 |
| Sfrisi, C | 1 |
| Kamal Al Yassini, A | 1 |
| Babuty, D | 2 |
| D'Hautefeuille, B | 1 |
| Scheck, F | 4 |
| Mycinsky, C | 1 |
| Pruvost, P | 1 |
| Peraudeau, P | 3 |
| el Allaf, D | 1 |
| Schifflers, E | 1 |
| Kormoss, N | 1 |
| Pisapia, A | 1 |
| Bine-Scheck, F | 3 |
| Schenowitz, A | 2 |
| Domerego, JJ | 2 |
| Maraud, L | 1 |
| Canler, A | 2 |
| Labban, N | 1 |
| Viart, R | 1 |
| Aubry, P | 1 |
| Beruben, E | 1 |
| Medvedowsky, JL | 3 |
| Dambrine, P | 2 |
| Garnier, LF | 2 |
| Labaki, F | 1 |
| Piechaczyk, P | 1 |
| Rouesnel, P | 3 |
| Touboul, P | 1 |
| Brembilla-Perrot, B | 2 |
| Gabriel, A | 1 |
| Lardoux, H | 2 |
| Marchand, X | 2 |
| Levy, S | 1 |
| Maison Blanche, P | 1 |
| Bleinc, D | 1 |
| Maison-Blanche, P | 1 |
| Fauchier, JP | 1 |
| Breuillac, JC | 1 |
| Funck, F | 1 |
| Piot, O | 1 |
| Flammang, D | 1 |
| Cheikel, J | 1 |
| Jouannon, C | 1 |
| Graux, P | 1 |
| Baudouy, Y | 1 |
| Leenhardt, A | 1 |
| Kühlkamp, V | 1 |
| Schmid, F | 1 |
| Risler, T | 1 |
| Seipel, L | 1 |
| Rothbart, ST | 1 |
| Saksena, S | 1 |
| Frances, Y | 1 |
| Luccioni, R | 1 |
| Delaage, M | 1 |
| Donnarel, G | 1 |
| Quiret, JC | 1 |
12 trials available for cifenline and Recrudescence
| Article | Year |
|---|---|
Randomized crossover study of the long-term effects of pilsicainide and cibenzoline in preventing recurrence of symptomatic paroxysmal atrial fibrillation: influence of the duration of arrhythmia before therapy.
Topics: Adult; Age Factors; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cross-Over Studies; Disease-F | 2006 |
Cibenzoline versus flecainide in the prevention of paroxysmal atrial arrhythmias: a double-blind randomized study.
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Drug Toleran | 1995 |
Cibenzoline in the prevention of recurrence of supraventricular arrhythmias.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Disease-Free Survival; Electrocardiograph | 1995 |
[Value of cibenzoline in the preventive treatment of recurrent atrial arrhythmia].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atr | 1994 |
[Study of the efficacy and tolerability of oral administration of cibenzoline in the prevention of recurrence of symptomatic atrial fibrillation].
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Electroc | 1994 |
[Comparative effects of cibenzoline and hydroquinidine in the prevention of auricular fibrillation. A randomized double-blind study].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Delayed-Action Preparations; Double-Blind | 1995 |
[Cibenzoline versus propafenone by the oral route for preventing recurrence of atrial arrhythmia: multicenter, randomized, double-blind study].
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation | 1996 |
[Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Double-Blind Method; Flecainide; Humans | 1997 |
[A randomized double-blind trial comparing cibenzoline and disopyramide in the prevention of recurrences of atrial tachyarrhythmia].
Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Disopyramide; Double-Blind Method; Female; Humans | 1998 |
Randomized comparison of flecainide and cibenzoline in the conversion of atrial fibrillation.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Chi-Square Distribution; Female; Flecainid | 1991 |
Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electric Stimul | 1986 |
[Long-term prevention of the recurrence of auricular fibrillation using cibenzoline. Multicenter study apropos of 89 case reports].
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; | 1985 |
1 other study available for cifenline and Recrudescence
| Article | Year |
|---|---|
Antiarrhythmic use of cibenzoline, a new class 1 antiarrhythmic agent with class 3 and 4 properties, in patients with recurrent ventricular tachycardia.
Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Imidazoles; Male; Middle Aged; Re | 1984 |